A detailed history of State Street Corp transactions in Kronos Bio, Inc. stock. As of the latest transaction made, State Street Corp holds 171,225 shares of KRON stock, worth $145,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171,225
Previous 175,301 2.33%
Holding current value
$145,541
Previous $217,000 21.2%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.92 - $1.5 $3,749 - $6,114
-4,076 Reduced 2.33%
171,225 $171,000
Q2 2024

Aug 14, 2024

SELL
$0.73 - $1.38 $2,190 - $4,140
-3,000 Reduced 1.68%
175,301 $217,000
Q2 2023

Aug 14, 2023

SELL
$1.24 - $1.92 $745,366 - $1.15 Million
-601,102 Reduced 77.12%
178,301 $306,000
Q1 2023

May 15, 2023

BUY
$1.34 - $2.62 $64,843 - $126,784
48,391 Added 6.62%
779,403 $1.14 Million
Q4 2022

Feb 14, 2023

SELL
$1.44 - $3.44 $5,885 - $14,059
-4,087 Reduced 0.56%
731,012 $1.18 Million
Q3 2022

Nov 15, 2022

BUY
$3.35 - $5.55 $52,159 - $86,413
15,570 Added 2.16%
735,099 $2.46 Million
Q2 2022

Aug 15, 2022

SELL
$3.12 - $7.52 $3.77 Million - $9.08 Million
-1,206,870 Reduced 62.65%
719,529 $2.62 Million
Q1 2022

May 16, 2022

BUY
$6.26 - $14.42 $2.82 Million - $6.5 Million
450,780 Added 30.55%
1,926,399 $13.9 Million
Q4 2021

Feb 14, 2022

BUY
$11.35 - $21.18 $9.35 Million - $17.4 Million
823,589 Added 126.31%
1,475,619 $20.1 Million
Q3 2021

Nov 15, 2021

BUY
$18.17 - $24.7 $1.98 Million - $2.69 Million
108,986 Added 20.07%
652,030 $13.7 Million
Q2 2021

Aug 16, 2021

BUY
$20.08 - $29.02 $6.4 Million - $9.25 Million
318,839 Added 142.21%
543,044 $13 Million
Q1 2021

May 17, 2021

SELL
$27.0 - $32.48 $10,800 - $12,991
-400 Reduced 0.18%
224,205 $6.56 Million
Q4 2020

Feb 16, 2021

BUY
$26.68 - $38.23 $5.99 Million - $8.59 Million
224,605 New
224,605 $6.71 Million

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $48.3M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.